Previous close | 7.00 |
Open | 7.00 |
Bid | 1.90 |
Ask | 3.80 |
Strike | 22.50 |
Expiry date | 2025-01-17 |
Day's range | 7.00 - 7.00 |
Contract range | N/A |
Volume | |
Open interest | 2 |
ROCKVILLE, MD, May 13, 2024 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (Nasdaq: MGNX), a biopharmaceutical company focused on developing, manufacturing and commercializing innovative monoclonal antibody-based therapeutics for the treatment of cancer, today announced that the Company's management will participate in the following investor conferences this month: The Citizens JMP Life Sciences Conference (New York). MacroGenics’ President & Chief Executive Officer, Scott Koenig, M.D., Ph.D., will parti
As you might know, MacroGenics, Inc. ( NASDAQ:MGNX ) last week released its latest first-quarter, and things did not...
Insight into Macrogenics' Financial Health and Future Clinical Prospects